Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora's Box of Multiple Myeloma

被引:14
作者
Garces, Juan-Jose [1 ]
San-Miguel, Jesus [1 ]
Paiva, Bruno [1 ]
机构
[1] Clin Univ Navarra, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Med Aplicada CIMA, Ctr Invest Biomed Red Oncol CIBERONC,Canc Ctr Uni, Navarra 31008, Spain
关键词
circulating tumor cell; CTC; liquid biopsy; multiple myeloma; transcriptomic characterization; genomic characterization; immunophenotype; MRD; flow cytometry; clinical trial; CLONAL PLASMA-CELLS; FLOW-CYTOMETRY; HIGH-RISK; PERIPHERAL-BLOOD; IDENTIFICATION; LEUKEMIA; QUANTIFICATION; CHALLENGES; PHENOTYPE; SURVIVAL;
D O I
10.3390/cancers14061430
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Bone marrow (BM) aspirates are mandatory for diagnosis and follow-up of patients with multiple myeloma (MM). However, they present two important caveats: Their invasiveness and limited scope to capture the broad tumor heterogeneity. Conversely, circulating tumor cells (CTCs) are detectable in the peripheral blood of patients with precursor and malignant disease states and have strong prognostic value. Moreover, the high genetic and transcriptomic overlap between both plasma cell compartments suggests that CTCs might reflect with notable precision the medullar clone. Furthermore, the study of CTCs could be used as a model to identify mechanisms favoring BM egression and disease spreading. Here, we summarize the state of the art on MM CTCs and provide insights on what they may offer in research and clinical scenarios. Bone marrow (BM) aspirates are the gold standard for patient prognostication and genetic characterization in multiple myeloma (MM). However, they represent an important limitation for periodic disease monitoring because they entail an aggressive procedure. Moreover, recent findings show that a single BM aspirate is unable to reflect the complex MM heterogeneity. Recent advances in flow cytometry, microfluidics, and "omics" technologies have opened Pandora's box of MM: The detection and isolation of circulating tumor cells (CTCs) offer a promising and minimally invasive alternative for tumor assessment and metastasis study. CTCs are detectable in premalignant and active MM states, and their enumeration has strong prognostic value, to the extent that it is challenging current stratification systems. In addition, CTCs reflect with high precision both intra- and extra-medullary disease at the phenotypic, genomic, and transcriptomic levels. Despite this high resemblance between tumor clones in distinct locations, some subtle (not random) differences might shed some light on the metastatic process. Thus, it has been suggested that a hypoxic and pro-inflammatory microenvironment could induce an arrest in proliferation forcing tumor cells to recirculate. Herein, we summarize data on the characterization of MM CTCs as well as their clinical and research potential.
引用
收藏
页数:11
相关论文
共 75 条
  • [1] Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
    Aceto, Nicola
    Bardia, Aditya
    Miyamoto, David T.
    Donaldson, Maria C.
    Wittner, Ben S.
    Spencer, Joel A.
    Yu, Min
    Pely, Adam
    Engstrom, Amanda
    Zhu, Huili
    Brannigan, Brian W.
    Kapur, Ravi
    Stott, Shannon L.
    Shioda, Toshi
    Ramaswamy, Sridhar
    Ting, David T.
    Lin, Charles P.
    Toner, Mehmet
    Haber, Daniel A.
    Maheswaran, Shyamala
    [J]. CELL, 2014, 158 (05) : 1110 - 1122
  • [2] Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients
    An, Gang
    Qin, Xiaoqi
    Acharya, Chirag
    Xu, Yan
    Deng, Shuhui
    Shi, Lihui
    Zang, Meirong
    Sui, Weiwei
    Yi, Shuhua
    Li, Zengjun
    Hao, Mu
    Feng, Xiaoyan
    Jin, Fengyan
    Zou, Dehui
    Qi, Junyuan
    Zhao, Yaozhong
    Tai, Yu-Tzu
    Wang, Jianxing
    Qiu, Lugui
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 (02) : 257 - 264
  • [3] Interactions of platelets with circulating tumor cells contribute to cancer metastasis
    Anvari, Sina
    Osei, Ernest
    Maftoon, Nima
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] Bataille R, 2006, HAEMATOLOGICA, V91, P1234
  • [5] A Mass Spectrometric-Derived Cell Surface Protein Atlas
    Bausch-Fluck, Damaris
    Hofmann, Andreas
    Bock, Thomas
    Frei, Andreas P.
    Cerciello, Ferdinando
    Jacobs, Andrea
    Moest, Hansjoerg
    Omasit, Ulrich
    Gundry, Rebekah L.
    Yoon, Charles
    Schiess, Ralph
    Schmidt, Alexander
    Mirkowska, Paulina
    Haertlova, Anetta
    Van Eyk, Jennifer E.
    Bourquin, Jean-Pierre
    Aebersold, Ruedi
    Boheler, Kenneth R.
    Zandstra, Peter
    Wollscheid, Bernd
    [J]. PLOS ONE, 2015, 10 (04):
  • [6] High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
    Bianchi, G.
    Kyle, R. A.
    Larson, D. R.
    Witzig, T. E.
    Kumar, S.
    Dispenzieri, A.
    Morice, W. G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2013, 27 (03) : 680 - 685
  • [7] BILLADEAU D, 1992, BLOOD, V80, P1818
  • [8] Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    Bolli, Niccolo
    Avet-Loiseau, Herve
    Wedge, David C.
    Van Loo, Peter
    Alexandrov, Ludmil B.
    Martincorena, Inigo
    Dawson, Kevin J.
    Iorio, Francesco
    Nik-Zainal, Serena
    Bignell, Graham R.
    Hinton, Jonathan W.
    Li, Yilong
    Tubio, Jose M. C.
    McLaren, Stuart
    Meara, Sarah O'
    Butler, Adam P.
    Teague, Jon W.
    Mudie, Laura
    Anderson, Elizabeth
    Rashid, Naim
    Tai, Yu-Tzu
    Shammas, Masood A.
    Sperling, Adam S.
    Fulciniti, Mariateresa
    Richardson, Paul G.
    Parmigiani, Giovanni
    Magrangeas, Florence
    Minvielle, Stephane
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Futreal, P. Andrew
    Anderson, Kenneth C.
    Campbell, Peter J.
    Munshi, Nikhil C.
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [9] FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
    Botta, Cirino
    Maia, Catarina
    Garces, Juan-Jose
    Termini, Rosalinda
    Perez, Cristina
    Manrique, Irene
    Burgos, Leire
    Zabaleta, Aintzane
    Alignani, Diego
    Sarvide, Sarai
    Merino, Juana
    Puig, Noemi
    Cedena, Maria-Teresa
    Rossi, Marco
    Tassone, Pierfrancesco
    Gentile, Massimo
    Correale, Pierpaolo
    Borrello, Ivan
    Terpos, Evangelos
    Jelinek, Tomas
    Paiva, Artur
    Roccaro, Aldo
    Goldschmidt, Hartmut
    Avet-Loiseau, Herve
    Rosinol, Laura
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Lahuerta, Juan-Jose
    Blade, Joan
    San-Miguel, Jesus F.
    Paiva, Bruno
    [J]. BLOOD ADVANCES, 2022, 6 (02) : 690 - 703
  • [10] Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
    Chaidos, Aristeidis
    Barnes, Chris P.
    Cowan, Gillian
    May, Philippa C.
    Melo, Valeria
    Hatjiharissi, Evdoxia
    Papaioannou, Maria
    Harrington, Heather
    Doolittle, Helen
    Terpos, Evangelos
    Dimopoulos, Meletios
    Abdalla, Saad
    Yarranton, Helen
    Naresh, Kikkeri
    Foroni, Letizia
    Reid, Alistair
    Rahemtulla, Amin
    Stumpf, Michael
    Roberts, Irene
    Karadimitris, Anastasios
    [J]. BLOOD, 2013, 121 (02) : 318 - 328